Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: October 13, 2005
Subject: Regulation FD Disclosure regarding FDA decision on New Drug Application (NDA).
Key Financial Metrics
This filing is a qualitative disclosure regarding regulatory status and does not contain quantitative financial data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- FDA Decision: Abbott received a "not-approvable" letter from the U.S. Food and Drug Administration (FDA) regarding the NDA for Xinlay (atrasentan).
- Indication: The rejection applies to the use of Xinlay in patients with metastatic hormone-refractory prostate cancer (HRPC).
- Advisory Committee: The FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend approval in September 2005.
- Ongoing Trials: The decision does not affect the ongoing trial M00-244, which evaluates Xinlay in patients with non-metastatic HRPC.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a caution that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations.
- Risk Factors: Economic, competitive, governmental, and technological factors affecting operations are referenced in the Form 10-Q for the period ended March 31, 2005.
- Regulatory Status: The filing is furnished pursuant to Regulation FD and is not intended to constitute a determination of materiality by Abbott.
Investor Verification Checklist
- Verify the specific clinical data and reasons cited in the FDA's not-approvable letter for Xinlay in metastatic HRPC.
- Review the status and design of the ongoing trial M00-244 for non-metastatic HRPC.
- Consult the Form 10-Q for the period ended March 31, 2005, for detailed risk factors regarding governmental and competitive influences.
- Monitor future communications for any updates on the Xinlay development program or potential resubmission plans.